Xenon Pharmaceuticals (NASDAQ:XENE) Director Gillian Cannon Sells 1,190 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Xenon Pharmaceuticals Price Performance

NASDAQ XENE traded down $0.52 on Monday, hitting $51.21. 1,181,045 shares of the company’s stock were exchanged, compared to its average volume of 1,258,214. The firm’s 50-day moving average price is $55.74 and its two-hundred day moving average price is $48.68. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $63.95. The firm has a market cap of $4.95 billion, a price-to-earnings ratio of -10.90 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.17). During the same period last year, the firm posted ($0.83) EPS. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on XENE. Royal Bank Of Canada increased their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th. HC Wainwright increased their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Wedbush lowered their target price on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, March 16th. Wolfe Research began coverage on Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $77.20.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Danske Bank A S bought a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $32,000. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $33,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $39,000. Finally, Osaic Holdings Inc. lifted its position in Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.